A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
Status:
Not yet recruiting
Trial end date:
2026-09-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early
or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment
epithelium and outer retinal atrophy (iRORA) or late AMD.